Literature DB >> 27006256

Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?

Marta Schirripa1, Heinz-Josef Lenz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27006256     DOI： 10.1038/nrgastro.2016.52

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  9 in total

1.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Sandra Misale; Rona Yaeger; Sebastijan Hobor; Elisa Scala; Manickam Janakiraman; David Liska; Emanuele Valtorta; Roberta Schiavo; Michela Buscarino; Giulia Siravegna; Katia Bencardino; Andrea Cercek; Chin-Tung Chen; Silvio Veronese; Carlo Zanon; Andrea Sartore-Bianchi; Marcello Gambacorta; Margherita Gallicchio; Efsevia Vakiani; Valentina Boscaro; Enzo Medico; Martin Weiser; Salvatore Siena; Federica Di Nicolantonio; David Solit; Alberto Bardelli
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.

Authors:  Jeffrey D Kearns; Raghida Bukhalid; Mark Sevecka; Gege Tan; Nastaran Gerami-Moayed; Shannon L Werner; Neeraj Kohli; Olga Burenkova; Callum M Sloss; Anne M King; Jonathan B Fitzgerald; Ulrik B Nielsen; Beni B Wolf
Journal:  Mol Cancer Ther       Date:  2015-04-24       Impact factor: 6.261

3.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Authors:  Giulia Siravegna; Benedetta Mussolin; Michela Buscarino; Giorgio Corti; Andrea Cassingena; Giovanni Crisafulli; Agostino Ponzetti; Chiara Cremolini; Alessio Amatu; Calogero Lauricella; Simona Lamba; Sebastijan Hobor; Antonio Avallone; Emanuele Valtorta; Giuseppe Rospo; Enzo Medico; Valentina Motta; Carlotta Antoniotti; Fabiana Tatangelo; Beatriz Bellosillo; Silvio Veronese; Alfredo Budillon; Clara Montagut; Patrizia Racca; Silvia Marsoni; Alfredo Falcone; Ryan B Corcoran; Federica Di Nicolantonio; Fotios Loupakis; Salvatore Siena; Andrea Sartore-Bianchi; Alberto Bardelli
Journal:  Nat Med       Date:  2015-06-01       Impact factor: 53.440

Review 4.  Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.

Authors:  Rodrigo Dienstmann; Ramon Salazar; Josep Tabernero
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Authors:  Sabrina Arena; Beatriz Bellosillo; Giulia Siravegna; Alejandro Martínez; Israel Cañadas; Luca Lazzari; Noelia Ferruz; Mariangela Russo; Sandra Misale; Iria González; Mar Iglesias; Elena Gavilan; Giorgio Corti; Sebastijan Hobor; Giovanni Crisafulli; Marta Salido; Juan Sánchez; Alba Dalmases; Joaquim Bellmunt; Gianni De Fabritiis; Ana Rovira; Federica Di Nicolantonio; Joan Albanell; Alberto Bardelli; Clara Montagut
Journal:  Clin Cancer Res       Date:  2015-01-26       Impact factor: 12.531

6.  Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Authors:  D Santini; B Vincenzi; R Addeo; C Garufi; G Masi; M Scartozzi; A Mancuso; A M Frezza; O Venditti; M Imperatori; G Schiavon; G Bronte; G Cicero; F Recine; E Maiello; S Cascinu; A Russo; A Falcone; G Tonini
Journal:  Ann Oncol       Date:  2012-03-05       Impact factor: 32.976

Review 7.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Authors:  M J Sorich; M D Wiese; A Rowland; G Kichenadasse; R A McKinnon; C S Karapetis
Journal:  Ann Oncol       Date:  2014-08-12       Impact factor: 32.976

Review 8.  Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

Authors:  Michael S Lee; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2015-05-29       Impact factor: 4.481

9.  The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

Authors:  Francisco J Sánchez-Martín; Beatriz Bellosillo; Mariona Gelabert-Baldrich; Alba Dalmases; Israel Cañadas; Joana Vidal; Alejandro Martinez; Guillem Argilés; Giulia Siravegna; Sabrina Arena; Klaus Koefoed; Laura Visa; Oriol Arpí; Ivan David Horak; Mar Iglesias; Christopher Stroh; Michael Kragh; Ana Rovira; Joan Albanell; Josep Tabernero; Alberto Bardelli; Clara Montagut
Journal:  Clin Cancer Res       Date:  2016-02-17       Impact factor: 12.531
  9 in total
  4 in total

1.  Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer.

Authors:  Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng; Zhen-Dong Chen; Haijun Zhong; Hongming Pan; Weijian Guo; Yongqian Shu; Ying Yuan; Jianfeng Zhou; Nong Xu; Tianshu Liu; Dong Ma; Changping Wu; Ying Cheng; Donghui Chen; Wei Li; Sanyuan Sun; Zhuang Yu; Peiguo Cao; Haihui Chen; Jiejun Wang; Shubin Wang; Hongbing Wang; Ning Wang; Bin Zhang; Qiang Zhang; Weiguo Su; Xiaojun Guo; Jin Li
Journal:  Onco Targets Ther       Date:  2021-08-11       Impact factor: 4.147

2.  Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.

Authors:  Rui-Hua Xu; Jin Li; Yuxian Bai; Jianming Xu; Tianshu Liu; Lin Shen; Liwei Wang; Hongming Pan; Junning Cao; Dongsheng Zhang; Songhua Fan; Ye Hua; Weiguo Su
Journal:  J Hematol Oncol       Date:  2017-01-19       Impact factor: 17.388

3.  Deoxycholic acid activates epidermal growth factor receptor and promotes intestinal carcinogenesis by ADAM17-dependent ligand release.

Authors:  Wenxiao Dong; Li Liu; Yan Dou; Mengque Xu; Tianyu Liu; Sinan Wang; Yujie Zhang; Baoru Deng; Bangmao Wang; Hailong Cao
Journal:  J Cell Mol Med       Date:  2018-06-29       Impact factor: 5.310

Review 4.  Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer.

Authors:  Jinjin Chu; Xianzhu Fang; Zhonghou Sun; Linlin Gai; Wenqing Dai; Haibo Li; Xinyi Yan; Jinke Du; Lili Zhang; Lu Zhao; Donghua Xu; Shushan Yan
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.